Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Core Insights - Compass Pathways plc has successfully achieved the primary endpoint in the ongoing Phase 3 COMP006 trial, which is the second of two Phase 3 trials evaluating COMP360 for treatment-resistant depression [1] Group 1 - The trial is assessing two fixed doses of COMP360, a synthetic, proprietary formulation of psilocybin [1] - The primary endpoint focused on the difference in change, indicating a significant milestone in the trial's progress [1]